Search

Claudio N Anasetti

from Saint Petersburg, FL
Age ~68
Get Report
Also known as:
Claudia Anasetti, Simone Anasetti
Phone and address:
555 5Th Ave NE STE 621, Saint Petersburg, FL 33701
(813) 482-6786
Related to:
Brianne Michelle Miller, 39Tiffany Rachelle Taylor, 31Nicholas Crefasi, 61Rita StellyDebra Morgan, 69Ann MillerTaunee Williams, 57
Connected to:
David Anash, 53Anastasia Anashkina, 49Emeka Anaso, 72Goodluck C Anaso, 35Dean C Anason, 56Christopher J Anasoulis, 30Leili Anassori, 35Diane A Anast, 76Philip A Anast, 61Catherine M Anastacio, 84

Claudio Anasetti Phones & Addresses

  • 555 5Th Ave NE STE 621, St Petersburg, FL 33701 (813) 482-6786
  • Saint Petersburg, FL
  • 15701 Richboro Ct, Tampa, FL 33647 (813) 972-3737
  • 7007 Maker St, Mercer Island, WA 98040 (206) 230-0912
  • Seattle, WA

Work

Company: Moffitt Cancer Center Address: 12902 Usf Magnolia Dr, Tampa, FL 33612 Phones: (813) 745-4673 (813) 449-8210

Education

School / High School: University Of Perugia, Italy-School Of Medicine

Languages

English • Italian

Awards

Healthgrades Honor Roll

Ranks

Certificate: Internal Medicine, 2005

Images

Specialities

Oncology

Professional Records

License Records

Claudio Anasetti

Address:
12902 Magnolia Dr, Tampa, FL
Phone:
(813) 745-5255
License #:
92747 - Active
Category:
Health Care
Issued Date:
Mar 4, 2005
Effective Date:
Jan 28, 2015
Expiration Date:
Jan 31, 2019
Type:
Medical Doctor

Claudio Anasetti

Address:
7007 SE Marker St, Mercer Island, WA
12902 Magnolia Dr, Tampa, FL
License #:
1553 - Expired
Category:
Health Care
Issued Date:
Mar 31, 2004
Effective Date:
Mar 4, 2005
Expiration Date:
Mar 31, 2006
Type:
Medical Faculty Certificate

Medicine Doctors

Claudio Anasetti Photo 1

Dr. Claudio Anasetti, Tampa FL - MD (Doctor of Medicine)

View page
Specialties:
Oncology
Address:
Moffitt Cancer Center
12902 Usf Magnolia Dr, Tampa, FL 33612
(813) 745-4673 (Phone), (813) 449-8210 (Fax)
Procedures:
Bone Marrow Transplant
Conditions:
Blood Cancer
Bone Marrow Transplant
Graft-Versus-Host Disease
Certifications:
Internal Medicine, 2005
Medical Oncology, 2006
Oncology
Awards:
Healthgrades Honor Roll
Languages:
English
Italian
Hospitals:
Moffitt Cancer Center
12902 Usf Magnolia Dr, Tampa, FL 33612

Florida Hospital Tampa
3100 East Fletcher Avenue, Tampa, FL 33613
Philosophy:
Dr. Claudio Anasetti is a senior member and chair of the Department of Blood and Marrow Transplant at Moffitt Cancer Center. He also directs Moffitt's blood and marrow transplant fellowship program and is a professor of oncology at the University of South Florida. Dr. Anasetti's research interests include the prevention and treatment of graft-versus-host disease, blood and bone marrow transplantation and immunogenetics and donor selection.
Education:
Medical School
University Of Perugia, Italy-School Of Medicine
Medical School
St Mary Hospital
Graduated: 1982
Medical School
University Of Perugia, Italy-Internal Medicine
Graduated: 1982
Medical School
Children's Memorial Hospital, Oklahoma City-Immunology
Graduated: 1983
Medical School
University Of Washington and Fred Hutchinson Cancer Research Center, Seattle, Wa-Oncology
Graduated: 1986
Claudio Anasetti Photo 2

Claudio Anasetti

View page
Specialties:
Medical Oncology
Work:
Moffitt Medical GroupMoffitt Cancer Center At International Plaza
4101 Jim Walter Blvd, Tampa, FL 33607
(813) 745-1600 (phone), (813) 558-1602 (fax)

Moffitt Medical GroupH Lee Moffitt Cancer Center
12902 Usf Magnolia Dr FL 3 FOB, Tampa, FL 33612
(813) 745-2557 (phone), (813) 745-8468 (fax)
Education:
Medical School
Univ Di Perugia, Fac Di Med E Chirurgia, Perugia, Italy
Graduated: 1980
Procedures:
Chemotherapy
Conditions:
Leukemia
Multiple Myeloma
Non-Hodgkin's Lymphoma
Acute Renal Failure
Acute Sinusitis
Languages:
English
Spanish
Description:
Dr. Anasetti graduated from the Univ Di Perugia, Fac Di Med E Chirurgia, Perugia, Italy in 1980. He works in Tampa, FL and 1 other location and specializes in Medical Oncology. Dr. Anasetti is affiliated with Moffitt Cancer Center and Tampa General Hospital.
Claudio Anasetti Photo 3

Claudio C Anasetti, Tampa FL

View page
Specialties:
Oncologist
Address:
12902 Usf Magnolia Dr, Tampa, FL 33612
Education:
University of Perugia, Faculty of Medicine and Surgery - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Claudio Anasetti
Oncology
Moffitt Cancer Center
Nonclassifiable Establishments · Specialty Hospital
4101 Jim Walter Blvd, Tampa, FL 33607
(813) 745-1600
Claudio Anasetti
Claudio Anasetti MD
Internist
12902 Usf Magnolia Dr, Tampa, FL 33612
(813) 979-7208

Publications

Us Patents

Radiation Delivery To Lymphoid And Marrow Tissues

View page
US Patent:
52737381, Dec 28, 1993
Filed:
Mar 3, 1990
Appl. No.:
7/562127
Inventors:
Dana C. Matthews - Seattle WA
Irwin D. Bernstein - Seattle WA
John A. Hansen - Mercer Island WA
Fred R. Appelbaum - Seattle WA
Claudio Anasetti - Seattle WA
Paul J. Martin - Seattle WA
Assignee:
Fred Hutchinson Cancer Research Center - Seattle WA
International Classification:
A61K 4300
A61K 4902
US Classification:
424 11
Abstract:
A method of selectively delivering radiation homogeneously to lymphoid and marrow tissues in vivo including the step of administering an effective dose of a radiolabeled immunological binding partner of a T-200 antigen to a patient is disclosed. Also disclosed are immunological binding partners and compositions based thereon for carrying out the method.

Mutated Nonactivating Igg2 Domains And Anti Cd3 Antibodies Incorporating The Same

View page
US Patent:
58345973, Nov 10, 1998
Filed:
May 31, 1996
Appl. No.:
8/656586
Inventors:
J. Yun Tso - Menlo Park CA
Michael S. Cole - San Francisco CA
Claudio Anasetti - Mercer Island WA
Assignee:
Protein Design Labs, Inc. - Mountain View CA
International Classification:
C07K 1600
US Classification:
5303873
Abstract:
The invention provides mutated IgG2 constant regions and anti-CD3 antibodies incorporating the same. Such antibodies specifically bind to the CD3 antigen on T-cells but induce reduced mitogenic response compared with otherwise identical antibodies bearing natural IgG2 constant regions. The antibodies can be used for treating disorders requiring immune suppression with fewer side effects than result from treatment with prior anti-CD3 antibodies.

Aurora Kinase And Janus Kinase Inhibitors For Prevention Of Graft Versus Host Disease

View page
US Patent:
20220281828, Sep 8, 2022
Filed:
Dec 20, 2021
Appl. No.:
17/555786
Inventors:
- Tampa FL, US
Said M. Sebti - Tampa FL, US
Harshani Lawrence - Tampa FL, US
Nicholas Lawrence - Tampa FL, US
Claudio Anasetti - Tampa FL, US
Joseph Pidala - Tampa FL, US
International Classification:
C07D 239/48
C07D 401/12
C07D 403/12
A61P 35/00
A61K 31/506
A61K 31/505
A61K 45/06
Abstract:
Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible T. In certain aspects, disclosed are compounds of Formula I-V.

Methods Of Treating Transplant Rejection

View page
US Patent:
20210069199, Mar 11, 2021
Filed:
Nov 16, 2020
Appl. No.:
17/099664
Inventors:
- Seattle WA, US
Xuezhong Yu - Seattle WA, US
Claudio Anasetti - Seattle WA, US
International Classification:
A61K 31/529
A61K 45/06
A61P 37/06
A61K 9/00
A61K 31/5355
Abstract:
The present invention provides the use of protein kinase inhibitors, in particular JAK2 inhibitors of formula (I), as set forth in the specification, in the treatment of solid organ transplant rejection and graft versus host disease (GvHD). Also provided are combination therapies for the treatment of solid organ transplant rejection and graft versus host disease.

Variant Survivin Vaccine For Treatment Of Cancer

View page
US Patent:
20200017561, Jan 16, 2020
Filed:
Aug 23, 2019
Appl. No.:
16/548989
Inventors:
- TAMPA FL, US
- PHILADELPHIA PA, US
SCOTT ANTONIA - LAND O'LAKES FL, US
CLAUDIO ANASETTI - SAINT PETERSBURG FL, US
DMITRY GABRILOVICH - VILLANOVA PA, US
International Classification:
C07K 14/47
A61K 39/00
A61P 35/00
Abstract:
The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.

Aurora Kinase And Janus Kinase Inhibitors For Prevention Of Graft Versus Host Disease

View page
US Patent:
20190127335, May 2, 2019
Filed:
Mar 13, 2017
Appl. No.:
16/083681
Inventors:
- Tamap FL, US
Said Sebti - Tampa FL, US
Harshani Lawrence - Tampa FL, US
Nicholas Lawrence - Tampa FL, US
Claudio Anasetti - Tampa FL, US
Joseph Pidala - Tampa FL, US
International Classification:
C07D 239/48
C07D 401/12
C07D 403/12
A61P 35/00
Abstract:
Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible T. In certain aspects, disclosed are compounds of Formula I-V.

Methods Of Treating Transplant Rejection

View page
US Patent:
20180318306, Nov 8, 2018
Filed:
Sep 28, 2016
Appl. No.:
15/764215
Inventors:
- Seattle WA, US
Xuezhong YU - Seattle WA, US
Claudio ANASETTI - Seattle WA, US
International Classification:
A61K 31/529
A61K 31/5355
A61K 9/00
A61P 37/06
Abstract:
The present invention provides the use of protein kinase inhibitors, in particular JAK2 inhibitors of formula (I), as set forth in the specification, in the treatment of solid organ transplant rejection and graft versus host disease (GvHD). Also provided are combination therapies for the treatment of solid organ transplant rejection and graft versus host disease.

Variant Survivin Vaccine For Treatment Of Cancer

View page
US Patent:
20180118798, May 3, 2018
Filed:
May 7, 2016
Appl. No.:
15/568967
Inventors:
- TAMPA FL, US
- Philadelphia PA, US
SCOTT ANTONIA - LAND O'LAKES FL, US
CLAUDIO ANASETTI - SAINT PETERSBURG FL, US
DMITRY GABRILOVICH - VILLANOVA PA, US
International Classification:
C07K 14/47
A61K 39/00
A61P 35/00
Abstract:
The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.
Control profile
Claudio N Anasetti from Saint Petersburg, FL, age ~68 Get Report